FindTrial
Sign In

Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT05522556
Enrollment
Unknown
Registered
2022-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia Areata

Keywords

Alopecia Areata (AA), Alopecia, Patchy AA, Alopecia Universalis (AU), Alopecia Totalis (AT), Ophiasis, Eyelash Loss, Eyebrow Loss, Hair Loss

Brief summary

Provide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.

Detailed description

In Expanded Access, treating physicians are the Sponsors. Expanded Access requests from treating physicians may be submitted to www.pfizercares.com. Availability will depend on location and country.

Interventions

DRUGRitlecitinib

capsules

Sponsors

Pfizer
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum

Inclusion criteria

Must have ≥ 50% hair loss on scalp due to Alopecia Areata (AA) and be intolerant or have inadequate response to all commonly used AA therapies accessible in the country. Additional eligibility criteria may be required.

Contacts

Primary ContactPfizer Cares
PfizerCares@Pfizer.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026